We can help you meet the challenges of anti-infective development
The development of novel vaccines and treatments for infectious diseases is crucial to decreasing the global burden of disease. According to the WHO, while immunization prevents between 2-3 million deaths every year, only one in 10 vaccines will reach the populations that need them. At the same time, issues such as antimicrobial resistance pose a threat to the treatment and prevention of bacterial, parasitic, viral and fungal infections.
Meeting these unmet needs requires a comprehensive clinical development and commercial solution that takes into account issues such as seasonality of disease, conducting clinical studies in regions where the disease is endemic, conducting studies with pediatric subjects, and other hurdles unique to the development of products which will help to prevent and stem infectious diseases.
Develop an optimal path forward across your product’s lifecycle
Quintiles Infectious Diseases & Vaccines Center of Excellence (CoE), is a cross-functional team of therapeutic experts focused on helping customers optimize the strategy of their anti-infective drugs and vaccines. This team integrates expertise in adult and pediatric infectious diseases and public health with deep knowledge of clinical trial design and execution and product lifecycle development and strategy. Our therapeutic knowledge is combined with data-driven insights to improve the probability of therapeutic, regulatory, and commercial success. The Infectious Disease and Vaccines COE collaborates extensively with the Pediatric Center of Excellence.
Working with companies of any size, and studies across all phases, the CoE brings together a team poised to develop the optimal path forward for your product through technical expertise spanning study design (including adaptive trials), clinical operations, labs, epidemiology, and commercial, which are enabled by a global network of sites and integrated technology platforms that deliver rapid and predictable timelines, and more cost effective trials while optimizing clinical & commercial outcomes for:
Integrate the scientific, therapeutic, operational and commercial components of your programs for improved outcomes. Quintiles brings together a global team of infectious disease experts with expertise in conducting trials and developing commercial strategies for novel anti-infectives and vaccines in our Infectious Disease and Vaccines Center of Excellence (CoE). The CoE at Quintiles can also assist with and implement ancillary services including planning and design, biostatistics, medical writing, pharmacovigilance, data-safety management boards, and real-world late phase studies
- Received the “Best CRO” for the Vaccines Industry Excellence (ViE) award in 2011, 2012, 2013, and 2015.
- 99% Global average GCP and Protocol compliance for Vaccine studies since 2008
Recent articles from our experts
Recognizing true H5N1 infections in humans during confirmed outbreaks (article)
- Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. (abstract)
- Challenges in Conducting Tuberculosis Clinical Trials in Developing Countries (article)